In vitro interaction between ceftazidime and vancomycin/teicoplanin in the presence of azithromycin against Pseudomonas aeruginosa

被引:0
作者
Repetto, Barbara [1 ]
Palenzona, Alberto [1 ]
Cagnacci, Simone [1 ]
Debbia, Eugenio A. [1 ]
Marchese, Anna [1 ]
机构
[1] Univ Genoa, Inst Microbiol CA Romanzi, DISCAT, I-16132 Genoa, Italy
关键词
Pseudomonas aeruginosa; vancomycin; ceftazidime; azithromycin; drug combination; time-kill tests; selection of resistant strains;
D O I
10.1007/BF03175086
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Pseudomonas aeruginosa is an opportunistic pathogen, intrinsically resistant to many antibiotics and prone to acquire resistance against many drugs. It is assumed that agents that disorganise the structure of the outer membrane might allow the passage of other drugs into cell. To verify this hypothesis, ceftazidime (CAZ) has been tested in association with glycopeptides (GLYs) and azithromycin (AZI). Time-kill experiments were performed on a representative strain. CAZ in combination with GLYs showed 99, 90 and 10% of CFU/ml reduction in 33.9, 52.5 and 13.6% of the cases, respectively; the addition of AZI increased the incidence of 99% CFU/ml reduction to 42% of the cases. Indifference was the most common finding, and additive/synergism in the other cases. Present findings demonstrated that CAZ favourably reacted with GLYs in the presence of AZI.
引用
收藏
页码:439 / 442
页数:4
相关论文
共 25 条
[1]   Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of pseudomonas aeruginosa infections [J].
Burgess, DS .
CLINICAL INFECTIOUS DISEASES, 2005, 40 :S99-S104
[2]  
*CLIN LAB STAND I, 2005, 15 INFORM S
[3]   Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis:: a European consensus [J].
Döring, G ;
Conway, SP ;
Heijerman, HGM ;
Hodson, ME ;
Hoiby, N ;
Smyth, A ;
Touw, DJ .
EUROPEAN RESPIRATORY JOURNAL, 2000, 16 (04) :749-767
[4]  
DURACK DT, 1989, MECH MICROBIAL DIS
[5]  
Eliopolous GM., 1996, Antibiotics in laboratory medicine, P330
[6]  
FONTANA F, 2003, GIMMOC, V7, P35
[7]   Prescribing guidelines for severe Pseudomonas infections [J].
Giamarellou, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (02) :229-233
[8]   New antimicrobials in the management of cystic fibrosis [J].
Hoiby, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (02) :235-238
[9]   Macrolides for the treatment of Pseudomonas aeruginosa infections? [J].
Howe, RA ;
Spencer, RC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (02) :153-155
[10]   Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting [J].
Juan, C ;
Gutiérrez, O ;
Oliver, A ;
Ayestarán, JI ;
Borrell, N ;
Pérez, JL .
CLINICAL MICROBIOLOGY AND INFECTION, 2005, 11 (11) :887-892